SO
Solara Active Pharma Sciences Ltd (SOLARA)
₹676.20
Mkt cap
₹3,601 Cr
P/E ratio
843.00
P/B
1.95
Div yield
0.00%
ROE
−0.13%
ROCE
4.86%
EPS (TTM)
₹0.80
Book value
₹346
52W range
422–774
Sector
Healthcare
Price history
Previous close
Solara Active Pharma Sciences Ltd is engaged in business of manufacturing, production, processing, formulating, sale, import, export, merchandising, distributing, trading of APIs. [1] It was formed through demerger of API business from Strides Shasun Ltd (currently named as Stride Pharma Sciences). Subsequently, it also acquired the human API business from Sequent Scientific Ltd during the same time, making it a pure play API company. [2]
NSE SOLARABSE 541540
Health check
Cautious
ValuationExpensive
ProfitabilityWeak
GrowthModerate
TechnicalsBullish
52-week range
−12.64% from high₹676
₹422+60.24% from low₹774
Current
₹676.20
Prev close
₹680.00
Day
−0.56%
Price performance
1D
−0.56%
1W
−8.16%
1M
+7.36%
3M
+20.67%
6M
+42.03%
1Y
+9.90%
YTD
+16.18%
Financials
Revenue, profit & margin
P/E ratio
843.0×
SOLARA is 2,339% above the sector median of 34.6×
SOLARA843.0×
Sector median34.6×
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 352 | 425 | 212 | 299 | 363 | 347 | 300 | 273 | 319 | 314 | 349 | 387 | 382 | |
| Expenses | 333 | 388 | 374 | 290 | 322 | 286 | 243 | 228 | 262 | 279 | 312 | 330 | 320 | |
| Operating Profit | 19 | 38 | -162 | 10 | 42 | 61 | 58 | 45 | 57 | 35 | 37 | 58 | 62 | |
| OPM % | 5% | 9% | -76% | 3.3% | 12% | 18% | 19% | 17% | 18% | 11% | 11% | 15% | 16% | |
| Other Income | 2 | -4 | -62 | -120 | 1 | 0 | 1 | 6 | 1 | 0 | -7 | 6 | 3 | |
| Interest | 25 | 24 | 25 | 31 | 31 | 28 | 27 | 29 | 24 | 21 | 22 | 28 | 22 | |
| Depreciation | 26 | 26 | 26 | 25 | 25 | 25 | 25 | 24 | 24 | 24 | 26 | 26 | 27 | |
| Profit before tax | -29 | -17 | -275 | -167 | -13 | 8 | 8 | -2 | 11 | -10 | -17 | 10 | 16 | |
| Tax % | -35% | 0% | 0% | 53% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | |
| Net Profit | -19 | -17 | -275 | -255 | -13 | 8 | 8 | -2 | 11 | -10 | -17 | 10 | 16 | |
| EPS in Rs | -4.07 | -3.58 | -57.36 | -53.20 | -3.74 | 2.22 | 2.24 | -0.58 | 2.91 | -2.79 | -4.82 | 2.65 | 3.38 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
No reaction history yet.
No quarterly filings ingested yet.
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Shareholding
as of Jun 202641.93%Promoter
Promoters41.93%0.07
FIIs11.52%0.07
DIIs3.74%
Public42.79%0.13
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,837.30 | 34.90 | 4,40,830 | 0.87% | 2,901 | +5.95% | 15,300 | +10.46% | 20.53% |
| Divi's Lab. | ₹9,375.00 | 83.54 | 2,48,877 | 0.32% | 902 | +65.50% | 3,080 | +27.80% | 21.97% |
| Torrent Pharma. | ₹4,840.00 | 82.51 | 1,84,098 | 0.79% | 566 | +5.79% | 4,921 | +54.85% | 15.19% |
| Zydus Lifesci. | ₹1,160.00 | 23.77 | 1,15,710 | 0.09% | 990 | −35.09% | 8,017 | +21.96% | 21.14% |
| Cipla | ₹1,394.50 | 31.48 | 1,12,656 | 0.93% | 786 | −39.19% | 7,119 | +2.33% | 15.49% |
| Laurus Labs | ₹1,954.00 | 96.56 | 1,05,577 | 0.10% | 362 | +125.49% | 2,026 | +29.10% | 17.76% |
| Aurobindo Pharma | ₹1,734.00 | 26.39 | 99,771 | 0.23% | 1,032 | +28.11% | 9,150 | +16.30% | 12.86% |
| Solara Active | ₹742.05 | 843.40 | 3,601 | 0.00% | 16 | +55.04% | 382 | +19.57% | 4.86% |
| Median: 158 Co. | ₹433.90 | 34.56 | 2,205 | 0.08% | 13 | +29.57% | 164 | +18.57% | 14.96% |
Filings
Annual reports9
Concall transcripts54
TranscriptJul 2026PPTJul 2026RECJul 2026TranscriptMay 2026PPTMay 2026RECMay 2026TranscriptFeb 2026PPTFeb 2026RECFeb 2026TranscriptNov 2025PPTNov 2025RECNov 2025TranscriptJul 2025PPTJul 2025RECJul 2025TranscriptMay 2025RECMay 2025TranscriptJan 2025PPTJan 2025RECJan 2025TranscriptOct 2024PPTOct 2024RECOct 2024TranscriptJul 2024
Credit ratings6
Announcements5
Shareholder Meeting / Postal Ballot-Outcome of AGM 18 SepIntimation In Connection With The Receipt Of Rectification Order 28 Aug - Income tax rectification order drops Rs.161.92 crore demand for AY 2019-20 to nil.Announcement under Regulation 30 (LODR)-Newspaper Publication 26 Aug - Newspaper publication regarding the completion of dispatch of 9th AGM Notice and Annual reportBusiness Responsibility and Sustainability Reporting (BRSR) 25 Aug - Solara filed FY2025-26 BRSR, detailing ESG performance, workforce data, and sustainability targets.Reg. 34 (1) Annual Report. 25 Aug